Big Pharma Split (TSX:PRM) 5-Year Yield-on-Cost %: 0.00 (As of Jul. 11, 2026)


TSX:PRM Big Pharma Split Corp TSX:PRM
7 GF Score
Price C$11.61
GF Value C$1.80
View Full Analysis

What is Big Pharma Split 5-Year Yield-on-Cost %?

Big Pharma Split TSX:PRM 7 5-Year Yield-on-Cost % is 0.00 as of Jul. 11, 2026. GuruFocus rates TSX:PRM with a GF Score™ of 7/100 and a GF Value™ of C$1.80.

Big Pharma Split's yield on cost for the quarter that ended in Dec. 2025 was 0.00.


The historical rank and industry rank for Big Pharma Split's 5-Year Yield-on-Cost % or its related term are showing as below:


During the past 9 years, Big Pharma Split's highest Yield on Cost was 13.59. The lowest was 0.00. And the median was 8.84.


TSX:PRM's 5-Year Yield-on-Cost % is not ranked *
in the Asset Management industry.
Industry Median: 6.39
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

Big Pharma Split  (TSX:PRM) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.


Big Pharma Split 5-Year Yield-on-Cost % Related Terms


TSX:PRM vs BLK, BX, KKR: 5-Year Yield-on-Cost % Comparison

For the Asset Management subindustry, Big Pharma Split's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Big Pharma Split 5-Year Yield-on-Cost % vs Asset Management Industry

For the Asset Management industry and Financial Services sector, Big Pharma Split's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where Big Pharma Split's 5-Year Yield-on-Cost % falls into.


TSX:PRM
7GF Score
Big Pharma Split Corp TSX:PRM
5-Year Yield-on-Cost % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Big Pharma Split 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of Big Pharma Split is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5
Frequently Asked Questions Learn more about 5-Year Yield-on-Cost % →
What does a 5-Year Yield-on-Cost % of 0.00 mean?
Big Pharma Split (TSX:PRM) has a 5-Year Yield-on-Cost % of 0.00 as of Jul. 11, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Big Pharma Split and its competitors.
Is Big Pharma Split's 5-Year Yield-on-Cost % too high?
Big Pharma Split's current 5-Year Yield-on-Cost % is 0.00. Overall, Big Pharma Split has a GF Score™ of 7/100, reflecting its overall financial health beyond just this single metric.
How does Big Pharma Split's 5-Year Yield-on-Cost % compare to BLK and BX?
Big Pharma Split's 5-Year Yield-on-Cost % of 0.00 can be compared against companies in the Asset Management industry. The industry median 5-Year Yield-on-Cost % is 6.39. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for an Asset Management company?
The median 5-Year Yield-on-Cost % among Asset Management companies is 6.39, based on 1,113 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Big Pharma Split and its competitors. For the Asset Management industry, the median 5-Year Yield-on-Cost % is 6.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Big Pharma Split's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Big Pharma Split stock overvalued right now?
Big Pharma Split (TSX:PRM) has a current 5-Year Yield-on-Cost % of 0.00. The stock's GF Value™ is C$1.80, compared to a current price of C$11.61 — trading 545% above its estimated fair value. The current 5-Year Yield-on-Cost % is 0.00. Big Pharma Split's overall GF Score™ is 7/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Big Pharma Split (TSX:PRM), the current 5-Year Yield-on-Cost % is 0.00 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Big Pharma Split (TSX:PRM) Overvalued in 2026?

Based on GuruFocus' analysis, Big Pharma Split stock appears to be overvalued. The current stock price of C$11.61 is trading 545% above its estimated GF Value™ of C$1.80.

Key valuation signals for TSX:PRM:

  • 5-Year Yield-on-Cost %: 0.00
  • GF Value™: C$1.80 vs. price of C$11.61 (545% above fair value)
  • GF Score™: 7/100

No single metric tells the full story. See the TSX:PRM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Big Pharma Split Business Description

Other Exchanges PRM.PR.A.PFD:Canada
Address 610 Chartwell Road, Suite 204, Oakville, ON, CAN, L6J 4A5
Big Pharma Split Corp is a closed end mutual fund corporation. The investment objective of the company is to provide shareholders with fixed cumulative preferential quarterly cash distributions and regular monthly cash distributions. The company has a presence in the United States, France, and the United Kingdom.
7GF Score

Get the complete analysis for TSX:PRM

5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$11.61
Price
C$1.80
GF Value